Gilead’s Kite Gets FDA Approval for Faster CAR T Therapy Manufacturing

Gilead Sciences’ Kite Pharma received FDA approval for a faster manufacturing process for its CAR-T cell therapy, according to an announcement on Tuesday. Kite said that its manufacturing of Yescarta (axicabtagene ciloleucel) will now bring its median turnaround time from 16 to 14 days.